Skip to Main content Skip to Navigation
Journal articles

[Targeted therapies, prognostic and predictive factors in endocrine oncology].

Abstract : A better understanding of molecular mechanisms responsible for tumorigenesis has allowed the development of targeted drugs designed to improve the outcome of cancer. In endocrine tumors, several molecules have demonstrated efficacy in terms of progression free survival during phase III trials such as vandetanib and cabozantinib in medullary thyroid carcinoma, sorafenib in differentiated thyroid carcinoma and everolimus or sunitinib for pancreatic neuroendocrine tumors. Rare cancer network has allowed ongoing phase III trials in malignant pheochromocytoma and adrenocortical carcinoma. However, to date no specific predictive biomarker has yet been identified for a personalized cancer medicine. We review recent advances in endocrine oncology concerning molecular targets identification, targeted therapies and predictive or prognostic markers.
Document type :
Journal articles
Complete list of metadata

Cited literature [32 references]  Display  Hide  Download
Contributor : Marc Lombes Connect in order to contact the contributor
Submitted on : Friday, May 16, 2014 - 5:09:52 PM
Last modification on : Sunday, June 26, 2022 - 12:00:35 PM
Long-term archiving on: : Saturday, April 8, 2017 - 3:54:09 PM


Files produced by the author(s)




Ségolène Hescot, Eric Baudin, Françoise Borson-Chazot, Marc Lombes. [Targeted therapies, prognostic and predictive factors in endocrine oncology].. Annales d'Endocrinologie, Elsevier Masson, 2013, 74 Suppl 1, pp.S13-22. ⟨10.1016/S0003-4266(13)70017-9⟩. ⟨inserm-00931413⟩



Record views


Files downloads